Stay updated on TQ05105 Tablets in Refractory aGVHD Clinical Trial
Sign up to get notified when there's something new on the TQ05105 Tablets in Refractory aGVHD Clinical Trial page.

Latest updates to the TQ05105 Tablets in Refractory aGVHD Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA new Revision: v3.4.2 was added to the record history. The government-funding/operating-status notice and the previous Revision: v3.4.1 entry were removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check33 days agoChange DetectedAdded a site-wide notice about potential data delays due to a lapse in government funding and that the NIH Clinical Center is open, with links to cc.nih.gov and opm.gov. Updated the record history to include Revision: v3.4.1, replacing the prior v3.4.0.SummaryDifference0.9%

- Check40 days agoChange DetectedUI changes include a 'Show glossary' toggle, color-coded highlights for additions and deletions, and updated revision text (e.g., Revision: v3.4.0).SummaryDifference1%

- Check54 days agoChange DetectedThe study record history shows a new revision entry v3.3.4 added and the prior revision v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check76 days agoChange DetectedFooter updates include removal of the HHS Vulnerability Disclosure link and a new Revision: v3.3.3 entry. A Revision: v3.3.2 entry was removed.SummaryDifference0.2%

- Check91 days agoChange DetectedStudy status and recruitment status were updated on 2025-12-04, and the trial was marked as completed on 2025-12-08. The earlier 'Active, not recruiting' status appears to have been removed on 2024-08-06.SummaryDifference0.7%

Stay in the know with updates to TQ05105 Tablets in Refractory aGVHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TQ05105 Tablets in Refractory aGVHD Clinical Trial page.